The U.S. Federal Trade Commission (FTC) challenge to Illumina’s planned $1.2 billion acquisition of Pacific Biosciences (PacBio) on anti-competitiveness grounds is unlikely to weaken its standing as the dominant company in next-generation sequencing, three analysts have concluded . . .

Get GEN Edge Today!

The post Deal or No Deal: FTC Challenge Poses No Threat to Illumina, Analysts Agree appeared first on GEN – Genetic Engineering and Biotechnology News.